BACKGROUND: An increased incidence of urinary tract infections (UTIs) caused by ciprofloxacin-gentamicin-resistant Escherichia coli (CiGREC) has been observed in a tertiary care centre in Sherbrooke, Quebec. The risk factors for such infections remained unclear. METHODS: To determine risk factors for, and outcomes of, CiGREC UTIs, a case control study was conducted. Between 2000 and 2007, 93 cases and 186 controls were identified using laboratory records of patients with greater than 10(7) colony-forming units/L of E coli in a urinary specimen. Cases had E coli with minimum inhibitory concentration to ciprofloxacin of 4 mg/L or greater and minimum inhibitory concentration to gentamicin of 8 mg/L or greater (CiGREC), and controls had E coli with any other susceptibility pattern to ciprofloxacin and gentamicin. Clinical and laboratory data were collected. Adjusted odds ratios (AOR) and their 95% CIs were calculated by logistic regression. RESULTS: The prevalence of CiGREC increased sixfold during the study period. Risk factors associated with CiGREC UTI were advanced age, male sex, urological abnormality, domicile outside Sherbrooke, living in a nursing home (AOR 11.73; 95% CI 3.70 to 37.15), use of fluoroquinolones (AOR 15.24; 95% CI 5.42 to 42.83) or aminoglycosides (AOR 6.59; 95% CI 1.22 to 35.61) within the previous month, and use of fluoroquinolones during the preceding one to 12 months (AOR 2.45; 95% CI 1.06 to 5.62). Compared with controls, cases were more likely not to receive an active antibiotic as empirical or definitive treatment, and were more likely to relapse. INTERPRETATION: In the future, it may become necessary to avoid selecting as empirical therapy of urinary tract infection an antibiotic to which the patient has been recently exposed.
BACKGROUND: An increased incidence of urinary tract infections (UTIs) caused by ciprofloxacin-gentamicin-resistant Escherichia coli (CiGREC) has been observed in a tertiary care centre in Sherbrooke, Quebec. The risk factors for such infections remained unclear. METHODS: To determine risk factors for, and outcomes of, CiGREC UTIs, a case control study was conducted. Between 2000 and 2007, 93 cases and 186 controls were identified using laboratory records of patients with greater than 10(7) colony-forming units/L of E coli in a urinary specimen. Cases had E coli with minimum inhibitory concentration to ciprofloxacin of 4 mg/L or greater and minimum inhibitory concentration to gentamicin of 8 mg/L or greater (CiGREC), and controls had E coli with any other susceptibility pattern to ciprofloxacin and gentamicin. Clinical and laboratory data were collected. Adjusted odds ratios (AOR) and their 95% CIs were calculated by logistic regression. RESULTS: The prevalence of CiGREC increased sixfold during the study period. Risk factors associated with CiGREC UTI were advanced age, male sex, urological abnormality, domicile outside Sherbrooke, living in a nursing home (AOR 11.73; 95% CI 3.70 to 37.15), use of fluoroquinolones (AOR 15.24; 95% CI 5.42 to 42.83) or aminoglycosides (AOR 6.59; 95% CI 1.22 to 35.61) within the previous month, and use of fluoroquinolones during the preceding one to 12 months (AOR 2.45; 95% CI 1.06 to 5.62). Compared with controls, cases were more likely not to receive an active antibiotic as empirical or definitive treatment, and were more likely to relapse. INTERPRETATION: In the future, it may become necessary to avoid selecting as empirical therapy of urinary tract infection an antibiotic to which the patient has been recently exposed.
Authors: Ari Robicsek; Jacob Strahilevitz; George A Jacoby; Mark Macielag; Darren Abbanat; Chi Hye Park; Karen Bush; David C Hooper Journal: Nat Med Date: 2005-12-20 Impact factor: 53.440
Authors: James A Karlowsky; Mark E Jones; Clyde Thornsberry; Ian R Friedland; Daniel F Sahm Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: T G Emori; D H Culver; T C Horan; W R Jarvis; J W White; D R Olson; S Banerjee; J R Edwards; W J Martone; R P Gaynes Journal: Am J Infect Control Date: 1991-02 Impact factor: 2.918
Authors: Galo Peralta; M Blanca Sánchez; J Carlos Garrido; Inés De Benito; M Eliecer Cano; Luis Martínez-Martínez; M Pía Roiz Journal: J Antimicrob Chemother Date: 2007-07-20 Impact factor: 5.790
Authors: Michael R Mulvey; Elizabeth Bryce; David Boyd; Marianna Ofner-Agostini; Sara Christianson; Andrew E Simor; Shirley Paton Journal: Antimicrob Agents Chemother Date: 2004-04 Impact factor: 5.191
Authors: John M Stelling; Karin Travers; Ronald N Jones; Philip J Turner; Thomas F O'Brien; Stuart B Levy Journal: Emerg Infect Dis Date: 2005-06 Impact factor: 6.883
Authors: Rima H Hanna-Wakim; Soha T Ghanem; Mona W El Helou; Sarah A Khafaja; Rouba A Shaker; Sara A Hassan; Randa K Saad; Carine P Hedari; Rima W Khinkarly; Farah M Hajar; Marwan Bakhash; Dima El Karah; Imad S Akel; Mariam A Rajab; Mireille Khoury; Ghassan S Dbaibo Journal: Front Cell Infect Microbiol Date: 2015-05-26 Impact factor: 5.293